Results 301 to 310 of about 481,268 (346)

ChemInform Abstract: Nicotinic Acid Receptor Agonists [PDF]

ChemInform, 2008
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Graeme Semple, Jeremy G. Richman, P. Douglas Boatman   +2 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Nicotinic Agonists and Psychosis

Current Drug Target -CNS & Neurological Disorders, 2002
Schizophrenia patients have insufficient inhibitory processing of identical paired auditory stimuli. This deficient "auditory gating" is thought to have physiological relevance, and its severity correlates with certain measures of both positive and negative symptoms.
Johanna K. Simosky, Robert Freedman, Karen E. Stevens   +2 more
openaire   +3 more sources

Effects of nicotinic agonists on the NMDA receptor

Brain Research, 1991
The cholinergic nicotinic agonists (-)nicotine and lobeline were observed to partially inhibit whole-cell N-methyl-D-aspartate (NMDA)-induced responses in rat cortical neurons in culture. In addition we found that (-)nicotine, (+)nicotine, and lobeline, but not the nicotine metabolite (-)cotinine nor acetylcholine, were able to displace [3H]dizocilpine
Ian J. Reynolds, Elias Aizenman, Lian-Hong Tang   +2 more
openaire   +3 more sources

Attentional effects of nicotinic agonists in rats

Neuropharmacology, 2003
Nicotine can increase stimulus detection, response rate and speed in the five-choice serial reaction time task, a rodent test of attention. In the present experiments, four other nicotinic agonists with different pharmacological profiles were compared in the same procedure.
Mohammed Shoaib, Susan Wonnacott, Britta Hahn, Christopher G. V. Sharples, Ian P. Stolerman   +4 more
openaire   +3 more sources

Binding of semirigid nicotinic agonists to nicotinic and muscarinic receptors.

Molecular Pharmacology, 1989
Isoarecolone methiodide (1-methyl-4-acetyl-1,2,3,6-tetrahydropyridine methiodide) was previously shown to be among the most potent agonists tested at the frog neuromuscular junction. Because nicotinic receptors from different sources vary in their selectivities, isoarecolone methiodide as well as 19 additional congeners, most of which were also ...
C E, Spivak, J A, Waters, R S, Aronstam
openaire   +2 more sources

Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

, 2006
ContextVarenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine.ObjectiveTo determine the efficacy ...
D. Jorenby, J. Hays, N. Rigotti, S. Azoulay, E. Watsky, K. Williams, C. Billing, Jason Gong, K. Reeves   +8 more
semanticscholar   +1 more source

Pharmacotherapy for tobacco cessation: Nicotine agonists, antagonists, and partial agonists

Current Oncology Reports, 2007
Nicotine replacement therapies (NRT) were the main pharmacologic option for treatment of nicotine dependence until the early 1990s, when controlled clinical trials confirmed the efficacy of bupropion, the first treatment not based on nicotine. Varenicline, a partial agonist at nicotine receptors, gained US regulatory approval in 2006 for smoking ...
Maher Karam-Hage, Paul M. Cinciripini
openaire   +3 more sources

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial

, 2006
ContextThe α4β2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel α4β2 nAChR partial agonist, may be beneficial for smoking cessation.ObjectiveTo assess ...
D. Gonzales, S. Rennard, M. Nides, C. Oncken, S. Azoulay, C. Billing, Watsky Eric Jacob, Jason Gong, K. Williams, K. Reeves   +9 more
semanticscholar   +1 more source

The therapeutic potential of nicotine and nicotinic agonists for weight control

Expert Opinion on Investigational Drugs, 1999
Transdermal nicotine patches have been successfully introduced as a safe and powerful aid to smoking cessation; this has contributed to the rising interest in additional therapeutic applications for nicotine and synthetic nicotinic agonists. Nicotine and nicotinic agonists may have a therapeutic potential for a variety of disorders, including Alzheimer'
openaire   +3 more sources

Epibatidine, a novel nicotinic receptor agonist [PDF]

, 1994
It is speculated that nicotine receptor ligands might be of therapeutic benefit for the treatment of obesity, anxiety, and memory loss. With the exception of nicotine, few selective high-affinity agents exist. (-)Epibatidine (1), isolated from Ecuadoran frogs, shows structural resemblence to (-)nicotine (2). Molecular modeling studies reveal that the N
T. McHugh, Marietta Piattoni-Kaplan, W. Glassco, Anthony W. Bannon, James P. Sullivan, D. M. Wypij, Michael W. Decker, Richard A. Glennon, J. McKay, Malgorzata Dukat, Stephen P. Arneric, Diana L. Donnelly-Roberts, May El, Billy R. Martin, T. Y. Shen, R. H. Loring, Murali Gopalakrishnan, K. R. Creasy, David J. Anderson, M. I. Damaj, X. Zhang, John A. Rosecrans, D. Dumas   +22 more
openaire   +1 more source